Altimmune (ALT) News Today $7.00 +0.05 (+0.72%) Closing price 04:00 PM EasternExtended Trading$6.97 -0.03 (-0.37%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Altimmune to Participate in the Guggenheim SMID Cap Biotech ConferenceJanuary 29 at 7:30 AM | globenewswire.comAltimmune, Inc. (NASDAQ:ALT) Position Trimmed by Exchange Traded Concepts LLCExchange Traded Concepts LLC lessened its stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 26.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 159,573 shares of the company's stock after selling 57,188 shares during the quarter. ExJanuary 28 at 4:02 AM | marketbeat.comJPMorgan Chase & Co. Sells 191,848 Shares of Altimmune, Inc. (NASDAQ:ALT)JPMorgan Chase & Co. lowered its stake in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 65.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,912 shares of the coJanuary 28 at 3:11 AM | marketbeat.comBrokers Offer Predictions for Altimmune FY2029 EarningsJanuary 28 at 2:25 AM | americanbankingnews.comHC Wainwright Estimates Altimmune FY2029 EarningsAltimmune, Inc. (NASDAQ:ALT - Free Report) - Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Altimmune in a note issued to investors on Wednesday, January 22nd. HC Wainwright analyst P. Trucchio anticipates that the company will earn $1.3January 28 at 2:24 AM | marketbeat.comBrokers Issue Forecasts for Altimmune FY2029 EarningsAltimmune, Inc. (NASDAQ:ALT - Free Report) - HC Wainwright issued their FY2029 earnings per share estimates for Altimmune in a research note issued on Wednesday, January 22nd. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of $1.30 for the year. HC WainwriJanuary 27 at 2:28 AM | marketbeat.comAltimmune's SWOT analysis: pemvidutide potential drives stock outlookJanuary 24, 2025 | msn.comHC Wainwright Reiterates Buy Rating for Altimmune (NASDAQ:ALT)January 24, 2025 | americanbankingnews.comAltimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)January 23, 2025 | benzinga.comAltimmune’s Pemvidutide: A Promising Investment with Strong Buy Rating and Potential Revenue GrowthJanuary 23, 2025 | markets.businessinsider.comAltimmune's (ALT) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $12.00 price objective on shares of Altimmune in a research report on Wednesday.January 22, 2025 | marketbeat.comEvercore ISI Keeps Their Buy Rating on Altimmune (ALT)January 8, 2025 | markets.businessinsider.comStifel Initiates Coverage of Altimmune (ALT) with Buy RecommendationJanuary 8, 2025 | msn.comPromising Prospects for Altimmune: Buy Rating Backed by Upcoming Data Readout and Strategic ExpansionJanuary 8, 2025 | markets.businessinsider.comAltimmune (NASDAQ:ALT) Shares Gap Up - What's Next?Altimmune (NASDAQ:ALT) Shares Gap Up - Here's WhyJanuary 8, 2025 | marketbeat.comAltimmune (NASDAQ:ALT) Earns Buy Rating from Analysts at Stifel NicolausStifel Nicolaus began coverage on shares of Altimmune in a research note on Wednesday. They issued a "buy" rating and a $18.00 target price on the stock.January 8, 2025 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by BrokeragesAltimmune, Inc. (NASDAQ:ALT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight ratings firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy raJanuary 7, 2025 | marketbeat.comFrom Davids to Goliaths: the GLP-1R gold rushJanuary 3, 2025 | finance.yahoo.comGeode Capital Management LLC Has $10.24 Million Holdings in Altimmune, Inc. (NASDAQ:ALT)Geode Capital Management LLC lifted its holdings in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 4.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,668,004 shares of the company's stock afterJanuary 2, 2025 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Shares Bought by Barclays PLCBarclays PLC boosted its holdings in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 93.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 155,741 shares of the company's stock after purchasing an additional 75,December 31, 2024 | marketbeat.comAltimmune (NASDAQ:ALT) Shares Down 5.9% - Here's WhyAltimmune (NASDAQ:ALT) Trading Down 5.9% - Here's What HappenedDecember 30, 2024 | marketbeat.comAltimmune Could Find A Partner For Its Phase 3 ExerciseDecember 30, 2024 | seekingalpha.comJim Cramer on Altimmune, Inc. (ALT): ‘Healthcare Is So Out Of Fashion’December 28, 2024 | insidermonkey.comWe're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn RateDecember 25, 2024 | uk.finance.yahoo.comAltimmune, Inc. (NASDAQ:ALT) Shares Sold by State Street CorpState Street Corp decreased its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 12.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,413,827 shares of the company's stock after selling 495,459 shares duringDecember 24, 2024 | marketbeat.comAltimmune (NASDAQ:ALT) Stock Price Down 4.6% - Here's WhyAltimmune (NASDAQ:ALT) Shares Down 4.6% - Here's What HappenedDecember 23, 2024 | marketbeat.comB.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)December 21, 2024 | markets.businessinsider.comAltimmune, Inc: Altimmune Added to Nasdaq Biotechnology IndexDecember 19, 2024 | finanznachrichten.deAltimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock ReboundsDecember 19, 2024 | msn.comWhy Altimmune Was Such a Robustly Healthy Stock on ThursdayDecember 19, 2024 | fool.comAltimmune (NASDAQ:ALT) Trading 4.7% Higher - Time to Buy?Altimmune (NASDAQ:ALT) Trading 4.7% Higher - Should You Buy?December 19, 2024 | marketbeat.comAltimmune Added to Nasdaq Biotechnology IndexDecember 19, 2024 | globenewswire.comLightning Round: Ford's warranty problems will come back to haunt it, says Jim CramerDecember 18, 2024 | msn.comAltimmune (NASDAQ:ALT) Stock Price Down 5.1% - Should You Sell?Altimmune (NASDAQ:ALT) Trading Down 5.1% - Time to Sell?December 17, 2024 | marketbeat.comAltimmune 2025: Redefining Obesity And MASH TreatmentDecember 16, 2024 | seekingalpha.comVirtu Financial LLC Invests $674,000 in Altimmune, Inc. (NASDAQ:ALT)Virtu Financial LLC purchased a new stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 109,759 shares of the company's stock, valued at approximately $67December 15, 2024 | marketbeat.comAltimmune (NASDAQ:ALT) Shares Up 4.9% - Should You Buy?Altimmune (NASDAQ:ALT) Shares Up 4.9% - Should You Buy?December 13, 2024 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one hasDecember 13, 2024 | marketbeat.comPortolan Capital Management LLC Sells 579,266 Shares of Altimmune, Inc. (NASDAQ:ALT)Portolan Capital Management LLC lowered its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 90.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,976 shares of the company'sDecember 5, 2024 | marketbeat.comLooking At Altimmune's Recent Unusual Options ActivityDecember 4, 2024 | benzinga.comAltimmune CEO on what’s next for its experimental obesity drugDecember 3, 2024 | msn.comAltimmune, Inc. (NASDAQ:ALT) Stake Lifted by Bellevue Group AGBellevue Group AG increased its position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 43.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 863,660 shares of the coDecember 1, 2024 | marketbeat.comAltimmune to Participate at Two Upcoming Investor ConferencesNovember 26, 2024 | globenewswire.comDo Redditors Think That Altimmune Inc. (ALT) Has a Big Upside Potential?November 21, 2024 | msn.comHC Wainwright Decreases Earnings Estimates for AltimmuneAltimmune, Inc. (NASDAQ:ALT - Free Report) - Research analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Altimmune in a report released on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($1.28) per shareNovember 18, 2024 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight analysts that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given aNovember 18, 2024 | marketbeat.comAltimmune presents data on effect of pemvidutide on inflammatory lipidsNovember 15, 2024 | markets.businessinsider.comAltimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024November 15, 2024 | globenewswire.comWhat is B. Riley's Estimate for Altimmune FY2024 Earnings?Altimmune, Inc. (NASDAQ:ALT - Free Report) - Investment analysts at B. Riley lowered their FY2024 EPS estimates for shares of Altimmune in a research note issued on Wednesday, November 13th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings per share of ($1.40) for tNovember 15, 2024 | marketbeat.comWhat is B. Riley's Estimate for Altimmune Q1 Earnings?Altimmune, Inc. (NASDAQ:ALT - Free Report) - Investment analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for shares of Altimmune in a report released on Wednesday, November 13th. B. Riley analyst M. Mamtani anticipates that the company will post earnings per share of (November 14, 2024 | marketbeat.com Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address ALT Media Mentions By Week ALT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALT News Sentiment▼0.940.74▲Average Medical News Sentiment ALT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALT Articles This Week▼129▲ALT Articles Average Week Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tarsus Pharmaceuticals News Iovance Biotherapeutics News Wave Life Sciences News Apogee Therapeutics News Belite Bio News Amphastar Pharmaceuticals News Schrödinger News Indivior News Disc Medicine News Arcutis Biotherapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALT) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
